304 related articles for article (PubMed ID: 2170791)
41. Differential modulation by [D-Pen2, D-Pen5]enkephalin and dynorphin A-(1-17) of the inhibitory bladder motility effects of selected mu agonists in vivo.
Sheldon RJ; Nunan L; Porreca F
J Pharmacol Exp Ther; 1989 May; 249(2):462-9. PubMed ID: 2566676
[TBL] [Abstract][Full Text] [Related]
42. Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice.
Paul D; Bodnar RJ; Gistrak MA; Pasternak GW
Eur J Pharmacol; 1989 Sep; 168(3):307-14. PubMed ID: 2555205
[TBL] [Abstract][Full Text] [Related]
43. Selective antagonism by naltrindole of the antinociceptive effects of the delta opioid agonist cyclic[D-penicillamine2-D-penicillamine5]enkephalin in the rat.
Drower EJ; Stapelfeld A; Rafferty MF; de Costa BR; Rice KC; Hammond DL
J Pharmacol Exp Ther; 1991 Nov; 259(2):725-31. PubMed ID: 1658309
[TBL] [Abstract][Full Text] [Related]
44. Contribution of supraspinal mu- and delta-opioid receptors to antinociception in the rat.
Miaskowski C; Taiwo YO; Levine JD
Eur J Pharmacol; 1991 Dec; 205(3):247-52. PubMed ID: 1667910
[TBL] [Abstract][Full Text] [Related]
45. Evidence for delta receptor mediation of [D-Pen2,D-Pen5]-enkephalin (DPDPE) analgesia in mice.
Heyman JS; Mosberg HI; Porreca F
NIDA Res Monogr; 1986; 75():442-5. PubMed ID: 2828989
[TBL] [Abstract][Full Text] [Related]
46. Antinociceptive activity of [beta-methyl-2', 6'-dimethyltyrosine(1)]-substituted cyclic [D-Pen(2), D-Pen(5)]Enkephalin and [D-Ala(2),Asp(4)]Deltorphin analogs.
Bilsky EJ; Qian X; Hruby VJ; Porreca F
J Pharmacol Exp Ther; 2000 Apr; 293(1):151-8. PubMed ID: 10734164
[TBL] [Abstract][Full Text] [Related]
47. The effects of protection by D-Pen2-D-Pen5-enkephalin or D-Ala2-NMePhe4-Gly-ol-enkephalin against beta-chlornaltrexamine in the spinal cord on the antinociception induced by beta-endorphin administered intracerebroventricularly in the mouse.
Suh HW; Lim JS; Song DK; Kim YH; Tseng LF
Neuropeptides; 1994 Aug; 27(2):143-9. PubMed ID: 7991069
[TBL] [Abstract][Full Text] [Related]
48. Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptor in vivo.
Bilsky EJ; Bernstein RN; Hruby VJ; Rothman RB; Lai J; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):491-501. PubMed ID: 8613959
[TBL] [Abstract][Full Text] [Related]
49. Delta-1 opioid receptor-mediated antinociceptive properties of a nonpeptidic delta opioid receptor agonist, (-)TAN-67, in the mouse spinal cord.
Tseng LF; Narita M; Mizoguchi H; Kawai K; Mizusuna A; Kamei J; Suzuki T; Nagase H
J Pharmacol Exp Ther; 1997 Feb; 280(2):600-5. PubMed ID: 9023269
[TBL] [Abstract][Full Text] [Related]
50. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
Ward SJ; Takemori AE
J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
[TBL] [Abstract][Full Text] [Related]
51. Intracerebroventricular N-ethylmaleimide differentially reduces supraspinal opioid analgesia in mice.
Sánchez-Blázquez P; Ulibarri I; Garzón J
Eur J Pharmacol; 1989 Jul; 166(2):193-200. PubMed ID: 2676563
[TBL] [Abstract][Full Text] [Related]
52. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine.
Heyman JS; Williams CL; Burks TF; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1988 Apr; 245(1):238-43. PubMed ID: 2834537
[TBL] [Abstract][Full Text] [Related]
53. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
54. Evidence for a single functional opioid delta receptor subtype in the mouse isolated vas deferens.
Wild KD; Carlisi VJ; Mosberg HI; Bowen WD; Portoghese PS; Sultana M; Takemori AE; Hruby VJ; Porreca F
J Pharmacol Exp Ther; 1993 Feb; 264(2):831-8. PubMed ID: 8382281
[TBL] [Abstract][Full Text] [Related]
55. [D-Pen2-D-Pen5]enkephalin, a delta opioid agonist, given intracerebroventricularly in the mouse produces antinociception through medication of spinal GABA receptors.
Holmes BB; Fujimoto JM
Pharmacol Biochem Behav; 1994 Nov; 49(3):675-82. PubMed ID: 7862723
[TBL] [Abstract][Full Text] [Related]
56. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.
Bilsky EJ; Inturrisi CE; Sadée W; Hruby VJ; Porreca F
Pain; 1996 Dec; 68(2-3):229-37. PubMed ID: 9121809
[TBL] [Abstract][Full Text] [Related]
57. Mastoparan reduces the supraspinal analgesia mediated by mu/delta-opioid receptors in mice.
Sánchez-Blázquez P; Garzón J
Eur J Pharmacol; 1994 Jun; 258(1-2):159-62. PubMed ID: 7925596
[TBL] [Abstract][Full Text] [Related]
58. Role of nitric oxide/cyclic GMP in i.c.v. administered beta-endorphin- and (+)-cis-dioxolane-induced antinociception in the mouse.
Xu JY; Tseng LF
Eur J Pharmacol; 1994 Sep; 262(3):223-31. PubMed ID: 7813587
[TBL] [Abstract][Full Text] [Related]
59. Modulation of mu-mediated antinociception in the mouse involves opioid delta-2 receptors.
Porreca F; Takemori AE; Sultana M; Portoghese PS; Bowen WD; Mosberg HI
J Pharmacol Exp Ther; 1992 Oct; 263(1):147-52. PubMed ID: 1328602
[TBL] [Abstract][Full Text] [Related]
60. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
